QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,622 signal articles · 325 in last 24h · 112,499 total before filter · latest 18m ago
325last 24h
2137last 7d
380● bullish (7d)
184● bearish (7d)
204publishers
AllMacro301Earnings1207M&A92Regulatory23Product13Analyst20
✕ clear all filtersticker: LLYsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Bloomberg56d agoneutral
Snubbing Nvidia for Adobe Costs Florida Stock-Picker $50 Billion

(Bloomberg) -- It was 180 degrees off the hot trade on Wall Street. Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingIran’s Deputy Foreign Minister Confirms Deal Reached With USNetanyahu Pays a Political Price for Trump’s Iran DealUS Set to Offer Iran Broad Financial Gains in Peace DealSnub Nvidia Corp., the soaring king of artificial intelligence chips. Embrace Adobe Inc., a sinking casualty of AI disruptio

ADBEAVGOCRMLLYMSNOW
Big pharma taps UK playbook to pressure Europe on drug prices
Reuters Videos56d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices

<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing.&nbsp;</p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers.&nbsp;</p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs.&nbsp;</p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines.&nbsp;</p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up.&nbsp;</p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation.&nbsp;</p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to ​lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>

LLYPFE
Eli Lilly’s hottest drugs face a quiet new threat
TheStreet57d agoneutral
Eli Lilly’s hottest drugs face a quiet new threat

Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...

LLY
India's Electronics Mart eyes new markets as tech hubs fear job losses
Reuters59d agoneutral
India's Electronics Mart eyes new markets as tech hubs fear job losses

Hyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered ‌job losses could hurt consumer spending, a top executive said. The retailer gets ‌about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase ​and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.

INFYLLY
Bloomberg65d agoneutral
Pentagon Accuses Alibaba, Baidu of Aiding China’s Military

(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center

BABABIDUGMLLYMUSSNLF
Eli Lilly makes surprising retreat from major market
TheStreet67d agoneutral
Eli Lilly makes surprising retreat from major market

Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...

LLY
Eli Lilly scores a first in major pharma milestone
TheStreet72d agoneutral
Eli Lilly scores a first in major pharma milestone

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...

LLY
Investing.com73d agoneutral
Could GLP-1 drugs become oncology’s next big opportunity?

Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.

CLLYPFE
Eli Lilly sends strong message on vaccine strategy
TheStreet73d agoneutral
Eli Lilly sends strong message on vaccine strategy

Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...

LLY
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound
The Wall Street Journal76d agoneutral
Eli Lilly Stock on Track for Record as Insurance Coverage Expands for Zepbound

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

CVSLLYNVO
Small biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President
Reuters76d agoneutral
Small biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President

Small biotech firms "latch onto" AI more quickly than bigger firms, the head of ‌Chinese tech giant Tencent's healthcare division said on ‌Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly ​turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk ‌and Eli Lilly have ⁠announced AI-related collaborations with technology firms.

LLYNVO
CVS brings back coverage for Lilly's obesity drug Zepbound
Reuters77d agoneutral
CVS brings back coverage for Lilly's obesity drug Zepbound

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

CVSLLYNVO